Combination study of VB-111 with a checkpoint inhibitor in patients with non-small cell lung cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Ofranergene obadenovec (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 27 Dec 2017 According to a VBL Therapeutics media release, this trial is expected to begin in the first quarter of 2018.
- 14 Aug 2017 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018, according to a VBL Therapeutics media release.
- 27 Jun 2017 New trial record